Gammaked Background

Proven Effectiveness

GAMMAKEDTM HAS BEEN PROVEN EFFECTIVE FOR THE TREATMENT OF CIDP, PI AND ITP

Gammaked has been proven effective for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency (PI) disease, and idiopathic thrombocytopenic purpura (ITP).1-3


TREATMENT WITH GAMMAKED SHOWED SIGNIFICANT IMPROVEMENT OF SIGNS AND SYMPTOMS IN PATIENTS WITH CIDP

In a double-blind, placebo controlled clincal study (n=208) of subjects affected with CIDP, four disability scores improved and maintained significant improvement through week 24 (primary endpoint) and grip strength improved in both hands, in those who received Gammaked.3

Also, more than 87% of patients given Gammaked every 3 weeks maintained these improvements and did not relapse during the extension phase.3


GAMMAKED IS PROVEN TO PROTECT AGAINST INFECTIONS

According to the Immune Deficiency Foundation, most people with primary immunodeficiency suffer from sinus infections. That's why a reduced number of sinus infections is a great indicator that your IGIV therapy is working effectively.4

Gammaked demonstrated protection from severe infections and acute sinusitis and acute exacerbations of chronic sinusitits.1


GAMMAKED DOUBLES THE PLATELET COUNT IN CHRONIC ITP

Platelets circulate in the blood to control bleeding.5,6 For people with ITP, it is important that their therapy increases their platelet count to keep that count at a healthy level. 

In patients with chronic ITP and low platelet counts, Gammaked doubled patients' platelet counts and maintained this increase for more than four weeks, without the need for additional IGIV treatment.2

ASK YOUR DOCTOR IF GAMMAKED IS RIGHT FOR YOU


References1. Roifman CM, Schroeder H, Berger M, et al, and the IGIV-C in PID Study Group. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol. 2003;3:1325-1333. 2. Bussel JB, Eldor A, Kelton JG, et al, and the IGIV-C in ITP Study Group. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost. 2004;91:771-778. 3. Hughes RAC, Donofrio P, Bril V, et al, on behalf of the ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136-144. 4. Immune Deficiency Foundation. Primary immune deficiency diseases in America: the first national survey of patients and specialists. www.primaryimmune.org Accessed October 01, 2014. 5. Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2008. 6. Dorland's Illustrated Medical Dictionary. 27th ed. Philadelphia, PA: W.B. Saunders; 1988.